CSL is a leading global biotech company that develops and delivers innovative biotherapies to help people living with life-threatening medical conditions live full lives. CSL’s Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organisations. These partnerships provide funding and access to industry experts for scientists working on novel therapeutic strategies.
The 2021 Research Acceleration Initiative will focus on research projects that span a CSL Therapeutic Area and a Focus Area, and that are amenable to or include a Modality. These can be found here. Successful applicants will receive up to £145,000 p.a. for up to 2 years (max £290,000 funding). Researchers who wish to apply should email Meghana Patel to recieve the link to submit a 300 word online abstract by 28 February 2022.
